GPC3

(redirected from glypican-3)

GPC3

A gene on chromosome Xq26.1 that encodes glypican 3, a cell surface proteoglycan with heparan sulfate that inhibits the dipeptidyl peptidase activity of DPP4. It may be involved in modulating growth of mesodermal tissues, in IGF2-receptor interactions, and in cellular growth and tumourigenesis.

Molecular Pathology
Defects in GPC3 cause Simpson-Golabi-Behmel syndrome.
References in periodicals archive ?
Objective: To determine the frequency of immunohistochemically expression of Glypican-3 in hepatocellular carcinoma on liver biopsies.
Objective: To determine the diagnostic accuracy of Glypican-3 in differentiating hepatocellular carcinoma from metastatic liver tumours while taking histopathology as the gold standard.
AFTV has been shown to induce cytotoxic T lymphocytes specific to glypican-3, the protein frequently expressed in HCC [18].
Glypican-3 is a proteoglycan that is attached to the cell surface and plays an important role in cellular growth, differentiation, and migration.
On staining of hepatocytes (Figure 7(c)), alpha-fetoprotein (AFP), glypican-3, and arginase-1 were negative.
Antibodies included synaptophysin (Syn), chromogranin A (CgA), CD56, phosphoenolpyruvate carboxykinase (PCK), cytokeratin 19 (CK19), cytokeratin 7 (CK7), epithelial membrane antigen (EMA), glypican-3, and hepatocyte.
The hepatoid adenocarcinoma component usually expresses AFP and some may also express HepPar-1 [1, 11], arginase-1 [11], and glypican-3 [11].
Immunohistochemical examinations demonstrated that the carcinoma cell was positive for vimentin, AE1/AE3 (focal), CAM5.2 (focal), CK7 (focal), and CK19 (focal) but negative for EMA, S-100, SMA, desmin, H-caldesmon, DOG-1, HepPar-1, glypican-3, CD34, CD117, PDGFR-Alpha, CK20, bile stain, iron, and mucicarmine.
Some alternative immunological markers, such as HepPar1, glypican-3, CD34, and AFP, are helpful in differential diagnosis.[6],[7],[25],[26],[27]
Glypican-3.--Glypican-3 (GPC3) is an oncofetal protein that can be detected in 70% to 80% of HCCs but not in benign hepatocellular lesions, such as hepatocellular adenoma.